我們已在上線！進一步了解

ADARx Pharmaceuticals, Inc. Common Stock

ADRX

市值 US$18.9億

17.65 USD

-0.05

0.28%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

17.83

+0.18

1.02%

1天

-0.28%

5天

-0.73%

1個月

-8.79%

3個月

-8.79%

6個月

-8.79%

今年迄今

-8.79%

1年

-8.79%

5年

-8.79%

10年

-8.79%

關於： Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

醫療保健生物科技